Choose your preferred way to stay informed of new case launches and settlement deadlines
Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022. The Company disclosed that the absolute improvement in the symptom score fell from 19.7 in the first part of the trial to 15.6 in part 2. Following this news, shares of Blueprint dropped over 10% on the same day. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
In order to be eligible to join the BPMC class action lawsuit, you must have incurred a loss on shares of Blueprint purchased during the class period listed above.
TOP
